tumor cells contributes to tumor promotion in cancer-related inflammation. This potential involvement of E-cadherin expression in M2-polarized inflammation associated with cancers supports this possibility. Fusion of myeloid cells and malignant cells has been suggested to generate aggressive cancer cell clones and to be a source of myeloid traits in cancer/myeloid cell hybrids.3

Irrespective of its pathophysiologic significance, the finding of up-regulation of the E-cadherin/catenin complex in M2 macrophages may offer an invaluable tool to dissect the presence and significance of these cells in human pathology.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

REFERENCES


Conflict-of-interest disclosure: The authors declare no competing financial interests.

LYMPHOID NEOPLASIA

Comment on Arons et al, page 4687, and Forconi et al, page 4696

IG genes and hairy cell leukemia

Federico Caligaris-Cappio UNIVERSITA’ VITA-SALUTE, SAN RAFFAELE

In this issue of Blood, 2 articles on HCL demonstrate that standard cladribine treatment is ineffective if the IG genes of the leukemic cells are in the UM version1,2 and the IG genes used belong to the VH4-34 family.2

Hairy cell leukemia (HCL) is an uncommon chronic lymphoid malignancy of B-cell type. This malignancy owes its name to the prominent irregular cytoplasmic projections of the malignant cell and has several unusual and still elusive biological and clinical features. A variant (vHCL) may present with morphologic features intermediate between hairy cells (HCS) and prolymphocytes. A hairy cell is a highly activated B cell that appears to have undergone the sequence of reactions that in normal immune response occur upon stimulation by antigen, accessory cells, and cytokines. Several phenotypic features of HCS—including the distinctive pattern of microvilli and ruffles that characterize HC morphology—are explicable in this context.

![Graph showing IG genes and hairy cell leukemia](image-url)
Many patients with HCL are asymptomatic and can be observed for months or years before requiring treatment, an exception being vHCL, which tends to present with high disease burden. Therapy of HCL is indicated when the patient develops one or more of the following conditions: significant cytopenias with related symptoms, symptomatic splenomegaly (or uncommonly adenopathy), constitutional symptoms. When treatment is warranted, the purine analogs cladribine and pentostatin have replaced splenectomy and interferon as the initial agents of choice.1-3 Because of ease of administration and paucity of toxicities, a single cycle of cladribine has become the preferred standard treatment. The majority of patients achieve a durable response. However, a proportion of patients, irrespective of whether they are classical or vHCL, either fail to respond or rather rapidly relapse.

Thus, we come to the relevance of the 2 papers discussed. The question is whether it is possible to recognize at diagnosis which patient will fail cladribine and therefore who could be spared a useless therapy and considered for an alternative type of treatment. Following in the footsteps of chronic lymphocytic leukemia (CLL),4 where patients have a biased use of immunoglobulin heavy chain variable (IGHV) genes and the prognosis is significantly different according to the presence or the absence of IGHV somatic mutations, the 2 studies have investigated IG genes in 2 large series of patients. Forconi and colleagues have prospectively studied 53 cases included in a multicenter Italian clinical trial of newly diagnosed HCL.1 They prove that the presence of UM IGHV genes defines a minor subset of patients who are refractory to single-agent cladribine and have a more aggressive behavior (see top panel of the figure). In their series, 5 of 58 cases were cladribine failures and all 5 were UM (compared with only 1 of 53 beneficial responses). Arons and colleagues have retrospectively studied 82 patients, most seeking response). Arons and colleagues have retrospectively studied 82 patients, most seeking response (see bottom panel of the figure). All but one of the VH4–34+ cases were UM. VH4–34+ cases had strikingly significant lower response rate and progression-free survival after initial treatment with cladribine and experienced a shorter overall survival from diagnosis (see bottom panel of the figure). In the Italian series, 1 of 5 cladribine failure cases was VH4–34+. Plausibly, the difference in the VH4–34 frequency in the 2 studies reflects the differences in the patient populations (newly diagnosed vs poor prognosis) and in the study modality (prospective vs retrospective). The Italian study1 reinforces the concept brought up by Arons et al.2

The take-home message is that the study of IG genes has to become an integral part of the diagnostic workup in HCL, irrespective of whether the patient has a classic or a vHCL. The reason is that if the IG genes are in the UM version and the IG genes used belong to the VH4–34 family, standard cladribine treatment may be ineffective. Accordingly, in these patients, new forms of treatment including monoclonal antibodies are warranted and deserve specific multicenter trials. Not surprisingly, the clinical behavior of UM-HCL parallels that of UM-CLL, but new interesting questions emerge. The road is now open for clinicians and biologists to understand why VH4–34 is such a risky gene in HCL,2 whether it has something to do with the autoimmune complications that may occur in HCL and also whether the rather high incidence of TP53 disfunction detected in the UM cases1 may provide a clue to understanding the mechanism of cladribine resistance in the UM–HCL group and more generally to purine analogs.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

Comment on Falet et al, page 4729

Cracking the platelet WIP

Alastair W. Poole University of Bristol

In this issue of Blood, Falet and colleagues report how deletion of the gene for the WASp interacting protein WIP in mice causes a major defect in GPVI signaling and activation of platelets, mediated by binding of IgAs to the platelet surface.1

Wiskott–Aldrich syndrome (WAS) is a rare X-linked disorder of the blood, which is largely a product of mutations in the gene encoding the WAS protein.2 Patients present with a range of clinical phenotypes dependent on the nature of the mutation, but are often characterized by marked thrombocytopenia associated with reduced platelet volume and immunodeficiency with progressive lymphopenia. Several blood cell functions are altered, related to cytoskeletal function, including chemotactic migration, adhesion, and phagocytosis. However, the picture is complex because there is often an increase in granulocyte count, which is associated with autoimmune disease presentations, commonly including eczema, ulcerative colitis, and glomerular nephropathy with IgA deposits.

WASP is a 64-kDa protein with restricted expression in nonerythroid blood cells and is a major link between cellular signals and the cytoskeleton, regulating the Arp2/3 complex to nucleate new actin filaments.3 WIP is a widely expressed, 63-kDa proline-rich protein that is centrally involved in actin nucleation through its interaction with WASp. Importantly, many of the missense mutations that are observed in WAS patients occur in the N-terminal WH1 binding domain of WASp, which is the region of the protein responsible

blood | 19 NOVEMBER 2009 | VOLUME 114, NUMBER 21 | 4611

From www.bloodjournal.org by guest on July 15, 2017. For personal use only.
IG genes and hairy cell leukemia

Federico Caligaris-Cappio